Comparison of safety and efficacy of Tofogliflozin and Ipragliflozin in patients with type 2 diabetes - Comparison of safety and efficacy of Tofogliflozin and Ipragliflozin in patients with type 2 diabetes

Minami Osaka hospital0 sites24 target enrollmentJune 26, 2019

Conditionstype 2 diabetes

Overview

Phase: 未知
Intervention: Not specified
Conditions: type 2 diabetes
Sponsor: Minami Osaka hospital
Enrollment: 24
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

June 26, 2019

End Date

March 31, 2020

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Minami Osaka hospital

Eligibility Criteria

Inclusion Criteria

Not provided

Exclusion Criteria

•1\.Patients who have a history of severe ketosis, diabetic coma or pre\-coma within 6 weeks of study start. 2\.Patients who developed severe hypoglycemia (diabetic coma or pre\-coma, convulsions, etc. require assistance by a third party) within 6 weeks of study start. 3\.Patients who have a history of medically important renal diseases such as renal vascular occlusive disease, nephrectomy and renal transplantation. 4\.Patients who show symptoms of dysuria, anuria, oliguria or urinary retention 5\.Patients who developed urinary tract infections and genital infections with subjective symptoms within 6 weeks of the study start. 6\. Patients with proliferative retinopathy (however, patients with photocoagulation etc. who have stable symptoms can be included). 7\. Patients with severe gastrointestinal disorders within 2 weeks of the study, or patients with a history of severe gastrointestinal disorders. 8\.Patients with acute coronary syndrome, cerebrovascular disorder within 3 months. 9\. Women and lactating patients who may or may be pregnant. 10\. Patients with severe infections, before and after surgery, with serious trauma. 11\. Patients receiving systemic administration of corticosteroids. 12\.Patients who have severe liver dysfunction (a high level of AST or ALT of at least 100 U / L). 13\.Patients who have a history of allergies to the drugs intended for the study. 14\. Patients with a malignant tumor or a history of malignant tumor. 15\.Patients judged by the investigator as inappropriate as subjects.